JP2024547071A5 - - Google Patents
Info
- Publication number
- JP2024547071A5 JP2024547071A5 JP2024537092A JP2024537092A JP2024547071A5 JP 2024547071 A5 JP2024547071 A5 JP 2024547071A5 JP 2024537092 A JP2024537092 A JP 2024537092A JP 2024537092 A JP2024537092 A JP 2024537092A JP 2024547071 A5 JP2024547071 A5 JP 2024547071A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleosides
- gapmer oligonucleotide
- antisense gapmer
- oligonucleotide according
- tna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21215919.8 | 2021-12-20 | ||
| EP21215919 | 2021-12-20 | ||
| PCT/EP2022/086286 WO2023117738A1 (en) | 2021-12-20 | 2022-12-16 | Threose nucleic acid antisense oligonucleotides and methods thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024547071A JP2024547071A (ja) | 2024-12-26 |
| JP2024547071A5 true JP2024547071A5 (https=) | 2025-12-22 |
Family
ID=78957536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024537092A Pending JP2024547071A (ja) | 2021-12-20 | 2022-12-16 | トレオース核酸アンチセンスオリゴヌクレオチドおよびその方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240336920A1 (https=) |
| EP (1) | EP4453206A1 (https=) |
| JP (1) | JP2024547071A (https=) |
| CN (1) | CN118434860A (https=) |
| WO (1) | WO2023117738A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4332221A1 (en) * | 2022-08-29 | 2024-03-06 | Roche Innovation Center Copenhagen A/S | Threose nucleic acid antisense oligonucleotides and methods thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| JP4236812B2 (ja) | 1997-09-12 | 2009-03-11 | エクシコン エ／エス | オリゴヌクレオチド類似体 |
| ES2234563T5 (es) | 1999-02-12 | 2018-01-17 | Daiichi Sankyo Company, Limited | Nuevos análogos de nucleósidos y oligonucleótidos |
| US7053207B2 (en) | 1999-05-04 | 2006-05-30 | Exiqon A/S | L-ribo-LNA analogues |
| US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
| WO2004046160A2 (en) | 2002-11-18 | 2004-06-03 | Santaris Pharma A/S | Amino-lna, thio-lna and alpha-l-oxy-ln |
| WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
| WO2007090071A2 (en) | 2006-01-27 | 2007-08-09 | Isis Pharmaceuticals, Inc. | 6-modified bicyclic nucleic acid analogs |
| AU2007249349B2 (en) | 2006-05-11 | 2012-03-08 | Isis Pharmaceuticals, Inc. | 5'-Modified bicyclic nucleic acid analogs |
| US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
| ES2526295T5 (es) | 2006-10-18 | 2021-05-04 | Ionis Pharmaceuticals Inc | Compuestos antisentido |
| CA2688321A1 (en) | 2007-05-30 | 2008-12-11 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| DK2173760T4 (en) | 2007-06-08 | 2016-02-08 | Isis Pharmaceuticals Inc | Carbocyclic bicyclic nukleinsyreanaloge |
| AU2008272918B2 (en) | 2007-07-05 | 2012-09-13 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| WO2009067647A1 (en) | 2007-11-21 | 2009-05-28 | Isis Pharmaceuticals, Inc. | Carbocyclic alpha-l-bicyclic nucleic acid analogs |
| DK2356129T3 (da) | 2008-09-24 | 2013-05-13 | Isis Pharmaceuticals Inc | Substituerede alpha-L-bicykliske nukleosider |
| US9012421B2 (en) | 2009-08-06 | 2015-04-21 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
| EP2580228B1 (en) | 2010-06-08 | 2016-03-23 | Ionis Pharmaceuticals, Inc. | Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
| AU2011338682B2 (en) | 2010-12-06 | 2017-04-27 | Quark Pharmaceuticals, Inc. | Double stranded oligonucleotide compounds comprising threose modifications |
| EP2673361B1 (en) | 2011-02-08 | 2016-04-13 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| CA2828544A1 (en) | 2011-03-03 | 2012-09-07 | Quark Pharmaceuticals, Inc. | Oligonucleotide modulators of the toll-like receptor pathway |
| US10202599B2 (en) | 2011-08-11 | 2019-02-12 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
| EP2850092B1 (en) | 2012-04-09 | 2017-03-01 | Ionis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
| EP2855679B1 (en) | 2012-05-31 | 2018-07-18 | QBI Enterprises Ltd. | Therapeutic oligonucleotides comprising pyrazolotriazine nucleotide analogues |
| CN104837996A (zh) | 2012-11-15 | 2015-08-12 | 罗氏创新中心哥本哈根有限公司 | 抗apob反义缀合物化合物 |
| EP3027223A1 (en) * | 2013-07-31 | 2016-06-08 | QBI Enterprises Ltd. | Methods of use of sphingolipid polyalkylamine oligonucleotide compounds |
| CA2935426C (en) | 2014-01-30 | 2023-07-25 | F. Hoffmann-La Roche Ag | Polyoligomer compound with biocleavable conjugates for reducing or inhibiting expression of a nucleic acid target |
| US9765328B2 (en) * | 2014-11-25 | 2017-09-19 | Arizona Board Of Regents On Behalf Of Arizona State University | Nuclease-resistant DNA analogues |
-
2022
- 2022-12-16 WO PCT/EP2022/086286 patent/WO2023117738A1/en not_active Ceased
- 2022-12-16 EP EP22840045.3A patent/EP4453206A1/en active Pending
- 2022-12-16 JP JP2024537092A patent/JP2024547071A/ja active Pending
- 2022-12-16 CN CN202280084309.6A patent/CN118434860A/zh active Pending
-
2024
- 2024-06-20 US US18/749,156 patent/US20240336920A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4118348B2 (ja) | Ｇキャプ安定化したオリゴヌクレオチド | |
| JP2025165976A5 (https=) | ||
| EP1015469B2 (en) | Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues | |
| EP2885312B1 (en) | Method of preparing oligomeric compounds using modified capping protocols | |
| JP2005500025A5 (https=) | ||
| JP2003012688A (ja) | オリゴヌクレオチドｎ３’→ｐ５’ホスホルアミデート：合成および化合物；ハイブリダイゼーションおよびヌクレアーゼ耐性特性 | |
| JP2006502694A5 (https=) | ||
| EP2951191B1 (en) | Method of preparing oligomeric compounds using modified coupling protocols | |
| JPH06511492A (ja) | キラルリン結合を有するオリゴヌクレオチド | |
| JPH083186A (ja) | 修飾オリゴヌクレオチド、その調製およびその使用 | |
| JP2024547071A5 (https=) | ||
| EP4122943B1 (en) | Oligonucleotides comprising a phosphorotrithioate internucleoside linkage | |
| WO2002038578A1 (en) | Modified nucleosides and nucleotides and use thereof | |
| JP2024522272A5 (https=) | ||
| US20250376684A1 (en) | Threose nucleic acid antisense oligonucleotides and methods thereof | |
| Tomori et al. | Synthesis of 2′-O-[3-(N-methylsulfamoyl) propan-1-yl] ribothymidine as a potentially applicable 2′-modified nucleoside for antisense oligonucleotides | |
| EP4453206A1 (en) | Threose nucleic acid antisense oligonucleotides and methods thereof | |
| JP7467457B2 (ja) | 立体的に規定されたオリゴヌクレオチドの合成における活性化物質としてのピリジニウム塩 | |
| Mangla et al. | Advances in the synthesis and antisense technology applications of bridged nucleic acid monomers | |
| CN118680948B (zh) | 寡核苷酸及其在抗乙型肝炎病毒中的应用 | |
| Jung et al. | Synthesis and hybridization properties of oligonucleotides containing 6-membered azasugar nucleotides | |
| EP3830101B1 (en) | Oligonucleotides comprising a phosphorotrithioate internucleoside linkage | |
| JPWO2022250050A5 (https=) | ||
| WO2023224108A1 (ja) | ヌクレオシド誘導体及びその利用 | |
| JPWO2023112931A5 (https=) |